Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon

NICE recommends Xarelto for PE

The U.K.’s National Institute for Health and Care Excellence (NICE) issued a final draft guidance that recommends the anticoagulant rivaroxaban (Xarelto, Janssen Pharmaceuticals/Bayer Healthcare) in the treatment of pulmonary embolism (PE) and prevention of recurrent deep vein thrombosis (DVT) and PE after acute PE in adults.

Carolinas HealthCare System performs first-in-human stent graft implantation

Carolinas HealthCare System’s Sanger Heart & Vascular Institute became the first in the world to implant a branched stent graft specifically designed for branch vessel repair of thoracic aortic aneurysms on Thursday. This is the first arch graft available in a clinical trial and both the device and surgical approach are novel.

Endologix board member Roderick de Greef to retire; Thomas F. Zenty, III to stand for election as board member

Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Roderick de Greef will retire from the Board of Directors at the end of his current term, which ends on May 23, 2013, the date of the Company's annual shareholder meeting. Thomas F. Zenty, III will stand for election as a Class III director to fill the resulting vacant position at the upcoming annual shareholder meeting.

Bayer's investigational riociguat granted U.S. FDA priority review for pulmonary arterial hypertension and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension

Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH).

Thoracic-length Heli-FX Aortic Securement System receives CE mark

Aptus Endosystems, Inc. announced today that it received CE clearance for its thoracic-length Heli-FXTM System.

EU approves InspireMD's carotid embolic protection stent

InspireMD has received CE Mark approval for its self-expanding Nitinol carotid embolic protection stent (EPS), which is based on the MicroNet mesh protection platform technology used to treat heart attack patients with InspireMD’s coronary EPS stents, MGuard and MGuard Prime.

Cordis wraps up Flexible Stenting deal

Cordis has completed its acquisition of Flexible Stenting Solutions, a developer of flexible peripheral arterial, venous and biliary stents.

ACC slides: ORBIT II sheds light on atherectomy for calcified lesions

SAN FRANCISCO—Results from ORBIT II, a clinical trial designed to evaluate the safety and efficacy of the Diamondback 360° Orbital Atherectomy System to treat de novo severely calcified coronary lesions, were presented March 9 at the American College of Cardiology (ACC) scientific session.

Displaying 1409 - 1416 of 1638

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.